Nuvaila FDA Tuesday, October 31, 2023 0.00 Neutral

FDA Approves WEZLANA — Nuvaila Limited

Nuvaila Limited announced the 2023 FDA approval of WEZLANA, an intravenous ustekekinumab-auub, positioning the manufacturer to leverage significant market demand for chronic inflammatory treatments.

View original filing at SEC.gov →

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day